These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20642867)

  • 1. Remission makes its way to rheumatology.
    Sokka T; Mäkinen H
    Arthritis Res Ther; 2010; 12(4):129. PubMed ID: 20642867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical remission in rheumatoid arthritis and psoriatic arthritis.
    Lubrano E; Mesina F; Caporali R
    Clin Exp Rheumatol; 2018; 36(5):900-910. PubMed ID: 29600949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission as the treatment goal--the FIN-RACo trial.
    Sokka T; Mäkinen H; Puolakka K; Möttönen T; Hannonen P
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-74-6. PubMed ID: 17083766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.
    Rantalaiho V; Puolakka K; Korpela M; Hannonen P; Möttönen T
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S27-31. PubMed ID: 23073350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.
    Rantalaiho V; Sandström T; Koski J; Hannonen P; Möttönen T; Kaipiainen-Seppänen O; Yli-Kerttula T; Kauppi MJ; Uutela T; Malmi T; Julkunen H; Laasonen L; Kautiainen H; Leirisalo-Repo M;
    Arthritis Care Res (Hoboken); 2019 Nov; 71(11):1450-1458. PubMed ID: 30295425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in US Veterans: Effect of Specialty Care and Geographic Distance.
    Walsh JA; Pei S; Burningham Z; Penmetsa G; Cannon GW; Clegg DO; Sauer BC
    J Rheumatol; 2018 Mar; 45(3):430-436. PubMed ID: 29142040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.
    Möttönen T; Hannonen P; Leirisalo-Repo M; Nissilä M; Kautiainen H; Korpela M; Laasonen L; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Ilva K; Yli-Kerttula U; Puolakka K; Järvinen P; Hakola M; Piirainen H; Ahonen J; Pälvimäki I; Forsberg S; Koota K; Friman C
    Lancet; 1999 May; 353(9164):1568-73. PubMed ID: 10334255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).
    Leirisalo-Repo M; Kautiainen H; Laasonen L; Korpela M; Kauppi MJ; Kaipiainen-Seppänen O; Luosujärvi R; Luukkainen R; Karjalainen A; Blåfield H; Uutela T; Ilva K; Julkunen HA; Paimela L; Puolakka K; Moilanen E; Hannonen PJ; Möttönen T;
    Ann Rheum Dis; 2013 Jun; 72(6):851-7. PubMed ID: 22753402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Hannonen P; Kaipiainen-Seppänen O; Möttönen T; Kauppi M; Karjalainen A; Laiho K; Laasonen L; Hakola M; Peltomaa R; Leirisalo-Repo M;
    Ann Rheum Dis; 2014 Nov; 73(11):1954-61. PubMed ID: 23908187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis.
    Mäkinen H; Kautiainen H; Hannonen P; Möttönen T; Leirisalo-Repo M; Laasonen L; Korpela M; Blåfield H; Hakola M; Sokka T
    J Rheumatol; 2007 Feb; 34(2):316-21. PubMed ID: 17183623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment advances in psoriatic arthritis.
    Ruderman EM
    Curr Rheumatol Rep; 2005 Aug; 7(4):313-8. PubMed ID: 16045835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadsorption combined with antirheumatic drugs in the treatment of psoriatic arthritis with rheumatoid arthritis: A case report.
    Cui L; Zhu H; Du A; Chen H; Yang X; Lei Y
    Int J Rheum Dis; 2024 Jul; 27(7):e15259. PubMed ID: 39003782
    [No Abstract]   [Full Text] [Related]  

  • 16. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
    Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.
    Feely MG; O'Dell JR
    Curr Opin Rheumatol; 2010 May; 22(3):316-20. PubMed ID: 20190639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.
    Rantalaiho V; Kautiainen H; Korpela M; Puolakka K; Blåfield H; Ilva K; Hannonen P; Leirisalo-Repo M; Möttönen T;
    Ann Rheum Dis; 2014 Apr; 73(4):788-90. PubMed ID: 24297374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.